Skip to Content

Prostate Cancer Clinical Trials

MOSAIC-P: Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate 
Aims:The purpose of the study is to test a four-week mindfulness program that is intended to reduce stress and improve the quality of life in men with prostate cancer that has spread to other parts of the body.   Each participant will be separated into one of two meeting locations at random, although the class content will be the same. Classes will be held: 1) in-person at a NorthShore facility;  or 2) online allowing men to participate while staying at home. 
Principal Investigator: Britt Hanson, DO
IRB Approval Number: EH15-403
Sponsor: NorthShore University HealthSystem 
Contact: Interested patients should contact study coordinator Nick Kirwen at 847.503.4281
Open to Enrollment: Yes

SPORE: Tissue, Blood, and Urine Banking for the Robert H. Lurie Comprehensive Cancer Center Prostate Tissue Bank
Aims: This study involves the banking (storing) of prostate tissue, blood and urine. Information from the patient's medical records and treatment will be followed for an indefinite amount of time up to 75 years or more. The purpose of the study is to enable cancer researchers and other investigators attain a better understanding of the development of prostate cancer, its treatment, prevention, and cure.
Diagnosis: Prostate
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH01-129
Sponsor: Robert H. Lurie Comprehensive Cancer Center
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

PCCTC c16-168: A Randomized Phase II  Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) with DNA Repair Defects
Aims: The main purpose is to study abiraterone alone, olaparib alone or the combination of the two drugs to see which works better.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH17/285
Sponsor: University of Chicago/PCCTC
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

EA8153: Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
Aims: The main purpose is to study abiraterone alone or abiraterone in combination with the chemotherapy drug, Cabazitaxel, to see which two regimens work better.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH18-349
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients wtih Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Aims: The main purpose is to study is to see if giving Nivolumab before and after surgery for patients with high risk Renal Cell Cancer is better than the standard of care which is observation.
Principal Investigator: Nicklas Pfanzelter, MD
IRB Approval Number: EH19-305
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

AFT-19: A Phase 3 Study of Androgen Annihiliation in High-Risk Biochemically Relapsed Prostate Cancer
Aims: The purpose of this study which of the 3 treatment regimens is better at treating prostate Cancer:  1) degarelix, 2) degarelix and apalutamide, or 3) degarelix and apalutamide and abiraterone acetate/prednisone
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH17-287
Sponsor: Alliance Foundation Trial
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

Janssen 64091742PCR2001 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration Resistant Prostate Cancer and DNA-Repair Anomalies.
Aims: The main purpose of this study is to see if niraparib is useful to treat men with advanced prostate cancer. The safety of niraparib will also be studied.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH16-364
Sponsor: Janssen Research and Development, LLC
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment:
Yes


J1557: Overcoming Drug Resistance in Metastatic Castration-Resitant Prostate Cancer with Novel Combination of TGF-G Recepto Inhibitor LY2157299 and Enzalutamide: A Randomized, Multi-Site Phase II Study
Aims: The purpose is to test the effectiveness and safety of combining enzalutamide with LY2157299 in men with advanced castrate resistant prostate cancer.
Principal Investigator: 
Daniel Shevrin, MD
IRB Approval Number: 
EH19-186
Sponsor: 
Johns Hopkins University
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment:
 Yes